- Home
- CTRM vs ALXO Comparison
CTRM vs ALXO Comparison
Compare CTRM & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- ALXO
- Stock Information
- Founded
- CTRM 2016
- ALXO 2015
- Country
- CTRM Cyprus
- ALXO United States
- Employees
- CTRM N/A
- ALXO N/A
- Industry
- CTRM Marine Transportation
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- CTRM Consumer Discretionary
- ALXO Health Care
- Exchange
- CTRM Nasdaq
- ALXO Nasdaq
- Market Cap
- CTRM 20.5M
- ALXO 24.0M
- IPO Year
- CTRM N/A
- ALXO 2020
- Fundamental
- Price
- CTRM $2.09
- ALXO $0.64
- Analyst Decision
- CTRM
- ALXO Strong Buy
- Analyst Count
- CTRM 0
- ALXO 6
- Target Price
- CTRM N/A
- ALXO $3.30
- AVG Volume (30 Days)
- CTRM 30.4K
- ALXO 561.7K
- Earning Date
- CTRM 08-11-2025
- ALXO 08-12-2025
- Dividend Yield
- CTRM N/A
- ALXO N/A
- EPS Growth
- CTRM N/A
- ALXO N/A
- EPS
- CTRM N/A
- ALXO N/A
- Revenue
- CTRM $66,197,291.00
- ALXO N/A
- Revenue This Year
- CTRM N/A
- ALXO N/A
- Revenue Next Year
- CTRM N/A
- ALXO N/A
- P/E Ratio
- CTRM N/A
- ALXO N/A
- Revenue Growth
- CTRM N/A
- ALXO N/A
- 52 Week Low
- CTRM $1.98
- ALXO $0.40
- 52 Week High
- CTRM $5.08
- ALXO $2.79
- Technical
- Relative Strength Index (RSI)
- CTRM 35.44
- ALXO 57.73
- Support Level
- CTRM $2.07
- ALXO $0.60
- Resistance Level
- CTRM $2.14
- ALXO $0.69
- Average True Range (ATR)
- CTRM 0.04
- ALXO 0.06
- MACD
- CTRM -0.01
- ALXO 0.00
- Stochastic Oscillator
- CTRM 9.52
- ALXO 63.95
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.